Jonah Feldman

Sagar Lonial, MD, provides commentary on the key questions raised by recent data on lenalidomide maintenance for patients with newly-diagnosed multiple myeloma.

The iberdomide, daratumumab, and dexamethasone regimen was approved based on superior MRD negativity rate vs standard-of-care in relapsed/refractory multiple myeloma.

Three-year follow-up from the single-arm trial that led to talquetamab's approval showed durable progression-free survival and overall survival in heavily pretreated multiple myeloma.

EIK1001, an agonist of TLR 7 and 8, is being investigated in first-line advanced melanoma in combination with pembrolizumab.

NMDP research showed several states and regions at risk of limited access to hematopoietic cell transplantation that can save the lives of patients with cancer.

The FDA gave fast track designation to the anti-TNFR2 agent in combination with pembrolizumab in advanced platinum-resistant ovarian cancer.

The tumor-infiltrating lymphocyte therapy has demonstrated potential for more convenient tissue collection and administration, an unmet need in advanced melanoma.

The FDA approved vusolimogene oderparepvec-wtpg plus nivolumab for PD-1–refractory advanced melanoma after a 10-3 advisory vote in favor of the oncolytic therapy.

Bria-PROS+, an off-the-shelf, whole-cell immunotherapy, will advance into clinical trials in prostate cancer after the IND was cleared.

Neoadjuvant leukocyte interleukin injection demonstrated efficacy in a biomarker-selected population, supporting a planned phase 3 trial in the locally advanced resectable oral cancer setting.

Damon R. Reed, MD, compared the carefully-considered off-label use of trastuzumab deruxtecan with a clinical trial experience in 2 rare sarcoma subtypes.

Patients with advanced melanoma were treated with DOC1021, a dendritic cell vaccine.

The FDA expanded the use of the radioligand therapy to the hormone-sensitive setting in metastatic prostate cancer.

FDA advisers back RP1 plus nivolumab for anti–PD-1–refractory advanced melanoma, citing durable responses despite design concerns and awaiting confirmatory IGNYTE-3 data.

A B7-H3–targeted antibody-drug conjugate showed benefit vs chemotherapy in relapsed osteosarcoma.

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee is to determine whether data from the IGNYTE trial can support an accelerated approval of RP1 plus nivolumab.

In an interview, Brian C. Betts, MD, revealed how Roswell Park Comprehensive Cancer Center achieved a dramatic increase in patient survival after allogeneic hematopoietic cell transplant.

Results of a retrospective study suggest that response to immune checkpoint inhibitors in sarcoma may be linked to other factors besides level of tumor mutational burden or mismatch repair deficiency.

An oral combination of sirolimus and domatinostat is being used to treat patients with metastatic osteosarcoma and other sarcomas.

The MonumenTAL-6 study found significant improvement with the combination of teclistamab and talquetamab vs standard regimens in relapsed/refractory multiple myeloma.

The ProstACT SELECT trial demonstrated safety and antitumor activity for TLX591-Tx in a population selected by PSMA expression in metastatic castration-resistant prostate cancer.

The FDA will review the PARP inhibitor/androgen pathway receptor inhibitor combination in metastatic castration-sensitive prostate cancer in the fourth quarter of 2026.

The ADMIRE study specifically enrolls patients with cutaneous squamous cell carcinoma who would otherwise be excluded from trials due to organ transplant or other immunocompromised state.

The ENDURANCE study showed no difference in overall survival between 2 years of lenalidomide and indefinite treatment in standard-risk patients who did not receive autologous stem cell transplant.

In an interview, Joseph Mikhael, MD, MEd, discussed the impact of the approval of subcutaneous isatuximab and its on-body delivery system in multiple myeloma.

The phase 2 OPTIMAL-e trial combines the PSMA-targeted radioligand therapy with standard ADT and ARPI in metastatic hormone-sensitive prostate cancer.

The Himalayas-1 trial will investigate rinzimetostat in combination with darolutamide in patients who previously received abiraterone for metastatic castration-resistant prostate cancer.

A phase 1 trial of the radiotherapeutic determined a recommended phase 2 dose after promising activity in heavily pretreated multiple myeloma.

Tucidinostat plus nivolumab extends progression-free survival in treatment-naive advanced melanoma, offering a promising oral, chemo-free boost to frontline immunotherapy.

Analyses of the CASSIOPEIA trial showed that some patients' outcomes could be associated with disease features besides depth of response alone.